These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9289689)

  • 21. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hypotensive effectiveness of therapy combined enalapril and nitrendipine and influence on the quality of life].
    Bryl W; Cymerys M; Kujawska-Luczak M; Pupek-Musialik D
    Pol Merkur Lekarski; 2005 Mar; 18(105):287-90. PubMed ID: 15997634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
    Zheng S; Nath V; Coyne DW
    Am J Nephrol; 2007; 27(5):522-9. PubMed ID: 17700014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction.
    Guazzi MD; Campodonico J; Celeste F; Guazzi M; Santambrogio G; Rossi M; Trabattoni D; Alimento M
    Clin Pharmacol Ther; 1998 Jan; 63(1):79-86. PubMed ID: 9465844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strict volume control normalizes hypertension in peritoneal dialysis patients.
    Günal AI; Duman S; Ozkahya M; Töz H; Asçi G; Akçiçek F; Basçi A
    Am J Kidney Dis; 2001 Mar; 37(3):588-93. PubMed ID: 11228184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tailoring antihypertensive treatment: which patients, what therapy?
    Neal W
    J Am Osteopath Assoc; 1987 Feb; 87(2 Suppl):190-3. PubMed ID: 3030980
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypertensive patients with renal lesion].
    Takagi N
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():31-5. PubMed ID: 15250263
    [No Abstract]   [Full Text] [Related]  

  • 30. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
    Vaughan ED; Carey RM; Ayers CR; Peach MJ
    J Clin Endocrinol Metab; 1979 May; 48(5):869-71. PubMed ID: 219011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolution of captopril-induced rash after substitution of enalapril.
    Rotmensch HH; Vlasses PH; Ferguson RK
    Pharmacotherapy; 1983; 3(2 Pt 1):131-3. PubMed ID: 6304662
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hyperkalemia in hypertensive patients undergoing regular hemodialysis during enalapril and fosinopril therapy].
    Dimković N; Djordjević T; Popović J; Dimković S; Tirmenstajn-Janković B; Zivanović M; Bobanović-Hasković J
    Srp Arh Celok Lek; 2006; 134(1-2):44-8. PubMed ID: 16850577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Converting enzyme inhibitors in hemodialysis.
    Bazilinski N
    Int J Artif Organs; 1983 Mar; 6(2):62-4. PubMed ID: 6302010
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypotensive mechanisms of captopril--a counter-view.
    Lazar AI
    J Assoc Physicians India; 1996 Oct; 44(10):753. PubMed ID: 9251364
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of converting enzyme inhibition: studies in experimental animals.
    Dinicolantonio R; Mendelsohn FA; Takata Y; Hutchinson JS; Doyle AE
    Neth J Med; 1984; 27(4):153-60. PubMed ID: 6330589
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety profiles of the angiotensin-converting enzyme inhibitors.
    Warner NJ; Rush JE
    Drugs; 1988; 35 Suppl 5():89-97. PubMed ID: 3063490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
    Hess E; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of intradermal bradykinin are potentiated by angiotensin converting enzyme inhibitors in hypertensive patients.
    Ferner RE; Wilson D; Paterson JR; Wilkinson R; Rawlins MD
    Br J Clin Pharmacol; 1989 Mar; 27(3):337-42. PubMed ID: 2541753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hazards of fad diets in patients treated with ACE inhibitors.
    Sisodiya S; Hoffbrand BI
    Br J Hosp Med; 1993 Oct 20-Nov 2; 50(8):486-7. PubMed ID: 8275290
    [No Abstract]   [Full Text] [Related]  

  • 40. Intra-individual comparison of captopril and enalapril in patients undergoing regular haemodialysis.
    Sennesael J; Verbeelen D
    Eur J Clin Pharmacol; 1986; 30(3):257-62. PubMed ID: 3015637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.